Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
F. Stephen Hodi(Harvard University), Jedd D. Wolchok(Cornell University), Adil Daud(University of California, San Francisco), Andrea Perrone(Università Cattolica del Sacro Cuore), Roxana Dronca(Dana-Farber Cancer Institute), Omid Hamid(Cedars-Sinai Medical Center), Richard W. Joseph(Daiichi Sankyo (United States)), Wen-Jen Hwu(The University of Texas MD Anderson Cancer Center), Jeffrey S. Weber(NYU Langone Health), Peter Hersey(The University of Sydney), Richard Kefford(Broad Institute), Sunyu Kang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Amita Patnaik(South Texas Accelerated Research Therapeutics), Antoni Ribas(University of California, Los Angeles), Anthony M. Joshua(St Vincent's Hospital Sydney), Caroline Robert(Institut Gustave Roussy), Xiaoyun Li(Nanjing University), Tara C. Gangadhar(University of Pennsylvania), Darcy A. Hille(Merck & Co., Inc., Rahway, NJ, USA (United States)), Dahai Xue(Dana-Farber Cancer Institute), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 754
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k